Sinovac positions itself as a leading provider of biopharmaceutical products in China. The company has faced significant operational challenges, including compliance issues with Nasdaq filing requirements in 2025, triggering a delisting determination in November 2025. However, as of June 2026, the company has regained Nasdaq compliance after filing required annual and interim financial reports.
Cyborg Score Rationale
The company faces challenges indicated by its financial performance and may encounter hurdles in achieving sustainable growth. While the company remains under mandatory panel monitoring until May 20, 2027, recent compliance restoration suggests operational stabilization, though governance and filing disputes persist.
Top Insights
Company regained full Nasdaq compliance in June 2026 after filing 2025 annual report and meeting periodic filing requirements.
Remains under mandatory Nasdaq panel monitoring through May 2027, indicating conditional compliance status.
Company has experienced corporate governance disputes, including disputed shareholder meetings and interim board appointments by Antigua High Court.
Operates globally with focus on vaccine development and manufacturing across infectious disease categories.
Named Competitors
Sinopharm — Major Chinese state-backed vaccine manufacturer
Pfizer-BioNTech — Global vaccine leader with COVID-19 and other vaccines
Moderna — mRNA vaccine developer
Recent Developments
(June 2026) Regained compliance with Nasdaq Global Market listing requirements after meeting filing obligations.
(May 2026) Filed annual report on Form 20-F for year ended December 31, 2025.
(January 2026) Nasdaq Hearings Panel considered late-filing notice at hearing scheduled for January 8, 2026.
Open the full interactive Sinovac Biotech Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.